Lista de obras - Jean-Jacques Kiladjian - Dominio Público Uruguay

A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis.

artículo científico publicado en 2017

A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence

artículo científico publicado en 2016

Activation of cytotoxic T-cell receptor gammadelta T lymphocytes in response to specific stimulation in myelodysplastic syndromes.

artículo científico publicado en 2008

Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy

artículo científico publicado en 2018

An International MDS/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms.

artículo científico publicado en 2015

An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults

artículo científico publicado en 2015

Antibodies against human recombinant erythropoietin: an unusual cause of erythropoietin resistance

artículo científico publicado en 2002

Aplastic anaemia in a case of hereditary neutrophil Fcgamma receptor IIIb deficiency.

artículo científico publicado en 1997

Assessing Bone Marrow Activity in Patients with Myelofibrosis: Results of a Pilot Study of 18F-FLT PET.

artículo científico publicado en 2017

Association of a single-nucleotide polymorphism in the SH2B3 gene with JAK2V617F-positive myeloproliferative neoplasms

artículo científico publicado en 2014

Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL International Working Group

artículo científico publicado en 2016

Benefits and pitfalls of Peg-Interferon-α2a therapy in patients with myeloproliferative neoplasm-associated myelofibrosis, a French Intergroup of Myeloproliferative neoplasms (FIM) study.

artículo científico publicado en 2017

Changes in quality of life and disease-related symptoms in patients with polycythemia vera receiving ruxolitinib or standard therapy

artículo científico publicado en 2015

Chemotherapy for post-myelofibrosis acute myeloid leukemia: eradication of the leukemic clone but not the MPN clone

artículo científico publicado en 2016

Classification of myeloproliferative disorders in the JAK2 era: is there a role for red cell mass?

artículo científico publicado en 2007

Clinical and molecular response to interferon-α therapy in essential thrombocythemia patients with CALR mutations.

artículo científico publicado en 2015

Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT)

artículo científico publicado en 2014

Clinical outcome of 27 imatinib mesylate-resistant chronic myelogenous leukemia patients harboring a T315I BCR-ABL mutation

artículo científico publicado en 2007

Clonal Hematopoiesis and Atherosclerosis

artículo científico publicado en 2017

Clonal analysis of erythroid progenitors suggests that pegylated interferon alpha-2a treatment targets JAK2V617F clones without affecting TET2 mutant cells

artículo científico publicado en 2010

Coexistence of a myeloproliferative disorder and secondary polycythemia in the same patient

artículo científico publicado en 2012

Combination therapy of hydroxycarbamide with anagrelide in patients with essential thrombocythemia in the evaluation of Xagrid(R) efficacy and long-term safety study.

artículo científico publicado en 2013

Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies

scientific article published on 02 August 2013

Cooperativity of imprinted genes inactivated by acquired chromosome 20q deletions ⬇️

artículo científico publicado en 2013

Cooperativity of imprinted genes inactivated by acquired chromosome 20q deletions.

artículo científico publicado en 2013

Current therapies and their indications for the Philadelphia-negative myeloproliferative neoplasms.

artículo científico

Cytolytic function and survival of natural killer cells are severely altered in myelodysplastic syndromes

artículo científico publicado en 2006

Cytoreductive treatment patterns for essential thrombocythemia in Europe. Analysis of 3643 patients in the EXELS study

artículo científico publicado en 2012

Defects of immune surveillance offer new insights into the pathophysiology and therapy of myelodysplastic syndromes

artículo científico publicado en 2007

Diagnosis, pathogenesis and treatment of the myeloproliferative disorders essential thrombocythemia, polycythemia vera and essential megakaryocytic granulocytic metaplasia and myelofibrosis.

artículo científico publicado en 1999

Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: retrospective assessment in 1470 patients

artículo científico publicado en 2014

Distinct deregulation of the hypoxia inducible factor by PHD2 mutants identified in germline DNA of patients with polycythemia

artículo científico publicado en 2011

Does increasing the JAK2V617F assay sensitivity allow to identify more patients with MPN?

artículo científico publicado en 2012

Driver mutations' effect in secondary myelofibrosis: an international multicenter study based on 781 patients.

artículo científico publicado en 2016

Efficacy and safety of pegylated-interferon α-2a in myelofibrosis: a study by the FIM and GEM French cooperative groups.

artículo científico publicado en 2013

Efficacy and safety of ruxolitinib after and versus interferon use in the RESPONSE studies

artículo científico publicado en 2018

Emerging therapeutic paradigms to target the dysregulated Janus kinase/signal transducer and activator of transcription pathway in hematological malignancies

artículo científico publicado en 2014

Enhanced calreticulin expression in red cells of polycythemia vera patients harboring the JAK2V617F mutation.

artículo científico publicado en 2017

Essential thrombocythemias without V617F JAK2 mutation are clonal hematopoietic stem cell disorders

artículo científico publicado en 2006

Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM090

artículo científico publicado en 2013

European LeukemiaNet study on the reproducibility of bone marrow features in masked polycythemia vera and differentiation from essential thrombocythemia.

artículo científico publicado en 2017

Expression level and differential JAK2-V617F-binding of the adaptor protein Lnk regulates JAK2-mediated signals in myeloproliferative neoplasms.

artículo científico publicado en 2010

Extramedullary blastic transformation revealed by a prolonged fever during the course of a 5q- syndrome

artículo científico publicado en 2009

Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis

artículo científico publicado en 2020

From leeches to interferon: should cytoreduction be prescribed for all patients with polycythemia vera?

artículo científico publicado en 2020

Health-related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy

artículo científico publicado en 2013

High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a

artículo científico publicado en 2006

Identification of JAK2 mutations in canine primary polycythemia.

artículo científico publicado en 2011

Impact of bone marrow fibrosis grade in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: A study of the MYSEC group

artículo científico publicado en 2019

Impact of hydroxycarbamide and interferon-α on red cell adhesion and membrane protein expression in polycythemia vera.

artículo científico publicado en 2018

Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts.

artículo científico publicado en 2014

Interferon alfa in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms

scientific article published on 16 May 2011

Interferon alfa therapy in CALR-mutated essential thrombocythemia.

artículo científico publicado en 2014

Interferon and the treatment of polycythemia vera, essential thrombocythemia and myelofibrosis

artículo científico publicado en 2013

Interferon-alpha for the therapy of myeloproliferative neoplasms: targeting the malignant clone

artículo científico publicado en 2015

Interferon-alpha in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms. Status and perspectives

scientific article published on March 2011

Interferon-alpha therapy in bcr-abl-negative myeloproliferative neoplasms.

scientific article published on 09 October 2008

Interlaboratory development and validation of a HRM method applied to the detection of JAK2 exon 12 mutations in polycythemia vera patients

artículo científico publicado en 2010

Is life expectancy of polycythemia vera patients clearly different from that of the general population?

artículo científico publicado en 2005

Is there a role for the use of IFN-α in primary myelofibrosis?

artículo científico publicado en 2012

Is there consensus on consensus?

artículo científico publicado en 2016

JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis

artículo científico publicado en 2012

Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study

artículo científico publicado en 2017

Live and let (MPN cells) die!

artículo científico publicado en 2012

Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis.

artículo científico publicado en 2016

Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis.

artículo científico publicado en 2017

Long-term follow-up of JAK2 exon 12 polycythemia vera: a French Intergroup of Myeloproliferative Neoplasms (FIM) study

artículo científico publicado en 2020

Long-term incidence of hematological evolution in three French prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia.

artículo científico publicado en 2006

Long-term outcomes of polycythemia vera patients treated with pipobroman as initial therapy

artículo científico publicado en 2003

Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses.

artículo científico publicado en 2017

Long-term treatment with interferon alfa for myeloproliferative neoplasms

artículo científico publicado en 2017

Lu/BCAM-mediated cell adhesion as biological marker of JAK2V617F activity in erythrocytes of polycythemia vera patients.

artículo científico publicado en 2015

Luspatercept for the treatment of anemia in myelodysplastic syndromes and primary myelofibrosis

scientific article published on 02 January 2019

Markers of iron deficiency in patients with polycythemia vera receiving ruxolitinib or best available therapy.

artículo científico publicado en 2017

Megakaryocytes and platelets in myeloproliferative disorders

artículo científico publicado en 1997

Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations

artículo científico publicado en 2011

Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial

artículo científico publicado en 2017

Mutations in exon 12 of JAK2 are mainly found in JAK2 V617F-negative polycythaemia vera patients.

artículo científico publicado en 2008

Mutations with epigenetic effects in myeloproliferative neoplasms and recent progress in treatment: Proceedings from the 5th International Post-ASH Symposium

artículo científico publicado en 2011

Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or both

artículo científico publicado en 2016

Myeloproliferative neoplasms and personalized medicine: the perfect match?

artículo científico publicado en 2015

Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis

artículo científico

NF-kappaB constitutes a potential therapeutic target in high-risk myelodysplastic syndrome

artículo científico publicado en 2005

New mutations of MPL in primitive myelofibrosis: only the MPL W515 mutations promote a G1/S-phase transition

scientific article published on 05 June 2008

Novel insights into the biology and treatment of chronic myeloproliferative neoplasms

artículo científico publicado en 2014

PEG-IFN-alpha-2a therapy in patients with myelofibrosis: a study of the French Groupe d'Etudes des Myelofibroses (GEM) and France Intergroupe des syndromes Myéloprolifératifs (FIM)

artículo científico publicado en 2009

Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial

artículo científico publicado en 2017

Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera

article

Phenotype variability of patients with post polycythemia vera and post essential thrombocythemia myelofibrosis is associated with the time to progression from polycythemia vera and essential thrombocythemia.

artículo científico publicado en 2018

Philadelphia chromosome-negative chronic myeloproliferative neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

scientific article published on 04 August 2015

Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet.

artículo científico publicado en 2018

Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet.

artículo científico publicado en 2011

Prognostic impact of JAK2V617F mutation in myelodysplatic syndromes: A matched case control study

artículo científico publicado en 2013

Proto-oncogene c-mpl is involved in spontaneous megakaryocytopoiesis in myeloproliferative disorders

artículo científico publicado en 1996

Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin

artículo científico publicado en 2002

RBC-transfusion guidelines update

artículo científico publicado en 2012

Rare Cancers and Social Media: Analysis of Twitter Metrics in the First 2 Years of a Rare-Disease Community for Myeloproliferative Neoplasms on Social Media-#MPNSM.

artículo científico publicado en 2017

Relevance of the criteria commonly used to diagnose myeloproliferative disorder in patients with splanchnic vein thrombosis

artículo científico publicado en 2005

Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference.

scientific article published on 10 March 2009

Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project.

artículo científico publicado en 2013

Ruxolitinib for the treatment of patients with polycythemia vera.

artículo científico

Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study.

artículo científico publicado en 2017

Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial.

artículo científico

Ruxolitinib versus standard therapy for the treatment of polycythemia vera.

artículo científico publicado en 2015

SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor-Naïve Patients With Myelofibrosis

artículo científico publicado en 2017

SOCS3 inhibits TPO-stimulated, but not spontaneous, megakaryocytic growth in primary myelofibrosis.

artículo científico publicado en 2009

Selective testing for calreticulin gene mutations in patients with splanchnic vein thrombosis: A prospective cohort study

artículo científico publicado en 2017

Single-cell analysis reveals selection of TP53-mutated clones after MDM2 inhibition

artículo científico publicado en 2022

Social Media and Myeloproliferative Neoplasms (MPN): Analysis of Advanced Metrics From the First Year of a New Twitter Community: #MPNSM.

artículo científico publicado en 2016

Study of the thrombopoitin receptor in essential thrombocythemia

artículo científico publicado en 1997

Symptom burden profile in myelofibrosis patients with thrombocytopenia: Lessons and unmet needs

artículo científico publicado en 2017

Symptomatic Profiles of Patients With Polycythemia Vera: Implications of Inadequately Controlled Disease.

artículo científico publicado en 2015

TET2 gene sequencing may be helpful for myeloproliferative neoplasm diagnosis

artículo científico publicado en 2014

The JAK2 46/1 haplotype in splanchnic vein thrombosis.

artículo científico publicado en 2011

The JAK2 V617F mutation identifies a subgroup of MDS patients with isolated deletion 5q and a proliferative bone marrow

artículo científico publicado en 2006

The first international meeting on V617F JAK2 mutation and its relevance in Philadelphia-negative myeloproliferative disorders.

artículo científico publicado en 2006

The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases

artículo científico publicado en 2008

The renaissance of interferon therapy for the treatment of myeloid malignancies

artículo científico publicado en 2011

The role of LNK/SH2B3 genetic alterations in myeloproliferative neoplasms and other hematological disorders

artículo científico publicado en 2017

The role of sexuality symptoms in myeloproliferative neoplasm symptom burden and quality of life: An analysis by the MPN QOL International Study Group

artículo científico publicado en 2016

The spectrum of JAK2-positive myeloproliferative neoplasms

artículo científico

The use of erythropoiesis-stimulating agents with ruxolitinib in patients with myelofibrosis in COMFORT-II: an open-label, phase 3 study assessing efficacy and safety of ruxolitinib versus best available therapy in the treatment of myelofibrosis

artículo científico

Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis

artículo científico publicado en 2013

Treatment of essential thrombocythemia in Europe: a prospective long-term observational study of 3649 high-risk patients in the Evaluation of Anagrelide Efficacy and Long-term Safety study

artículo científico publicado en 2017

Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980.

artículo científico publicado en 2011

Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM).

artículo científico publicado en 2010

Treatment strategies in essential thrombocythemia. A critical appraisal of various experiences in different centers

artículo científico publicado en 1996

Unraveling the genetic underpinnings of myeloproliferative neoplasms and understanding their effect on disease course and response to therapy: proceedings from the 6th International Post-ASH Symposium

artículo científico publicado en 2012

Use of the 46/1 haplotype to model JAK2(V617F) clonal architecture in PV patients: clonal evolution and impact of IFNα treatment.

artículo científico publicado en 2013

V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis

artículo científico publicado en 2005

Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project.

artículo científico publicado en 2018

What are RBC-transfusion-dependence and -independence?

scientific article published on 07 August 2010

Which patients with myelofibrosis should receive ruxolitinib therapy? ELN-SIE evidence-based recommendations.

artículo científico publicado en 2016

[Diagnosis and treatment of primary thrombocythemia]

artículo científico publicado en 2005

[Dysmegakaryocytopoiesis and dysthrombopoiesis in myeloproliferative syndromes]

scientific article published on 01 January 1996

Lista de obras de Jean-Jacques Kiladjian

A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis.

A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence

Activation of cytotoxic T-cell receptor gammadelta T lymphocytes in response to specific stimulation in myelodysplastic syndromes.

Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy

An International MDS/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms.

An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults

Antibodies against human recombinant erythropoietin: an unusual cause of erythropoietin resistance

Aplastic anaemia in a case of hereditary neutrophil Fcgamma receptor IIIb deficiency.

Assessing Bone Marrow Activity in Patients with Myelofibrosis: Results of a Pilot Study of 18F-FLT PET.

Association of a single-nucleotide polymorphism in the SH2B3 gene with JAK2V617F-positive myeloproliferative neoplasms

Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL International Working Group

Benefits and pitfalls of Peg-Interferon-α2a therapy in patients with myeloproliferative neoplasm-associated myelofibrosis, a French Intergroup of Myeloproliferative neoplasms (FIM) study.

Changes in quality of life and disease-related symptoms in patients with polycythemia vera receiving ruxolitinib or standard therapy

Chemotherapy for post-myelofibrosis acute myeloid leukemia: eradication of the leukemic clone but not the MPN clone

Classification of myeloproliferative disorders in the JAK2 era: is there a role for red cell mass?

Clinical and molecular response to interferon-α therapy in essential thrombocythemia patients with CALR mutations.

Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT)

Clinical outcome of 27 imatinib mesylate-resistant chronic myelogenous leukemia patients harboring a T315I BCR-ABL mutation

Clonal Hematopoiesis and Atherosclerosis

Clonal analysis of erythroid progenitors suggests that pegylated interferon alpha-2a treatment targets JAK2V617F clones without affecting TET2 mutant cells

Coexistence of a myeloproliferative disorder and secondary polycythemia in the same patient

Combination therapy of hydroxycarbamide with anagrelide in patients with essential thrombocythemia in the evaluation of Xagrid(R) efficacy and long-term safety study.

Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies

Cooperativity of imprinted genes inactivated by acquired chromosome 20q deletions ⬇️

Cooperativity of imprinted genes inactivated by acquired chromosome 20q deletions.

Current therapies and their indications for the Philadelphia-negative myeloproliferative neoplasms.

Cytolytic function and survival of natural killer cells are severely altered in myelodysplastic syndromes

Cytoreductive treatment patterns for essential thrombocythemia in Europe. Analysis of 3643 patients in the EXELS study

Defects of immune surveillance offer new insights into the pathophysiology and therapy of myelodysplastic syndromes

Diagnosis, pathogenesis and treatment of the myeloproliferative disorders essential thrombocythemia, polycythemia vera and essential megakaryocytic granulocytic metaplasia and myelofibrosis.

Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: retrospective assessment in 1470 patients

Distinct deregulation of the hypoxia inducible factor by PHD2 mutants identified in germline DNA of patients with polycythemia

Does increasing the JAK2V617F assay sensitivity allow to identify more patients with MPN?

Driver mutations' effect in secondary myelofibrosis: an international multicenter study based on 781 patients.

Efficacy and safety of pegylated-interferon α-2a in myelofibrosis: a study by the FIM and GEM French cooperative groups.

Efficacy and safety of ruxolitinib after and versus interferon use in the RESPONSE studies

Emerging therapeutic paradigms to target the dysregulated Janus kinase/signal transducer and activator of transcription pathway in hematological malignancies

Enhanced calreticulin expression in red cells of polycythemia vera patients harboring the JAK2V617F mutation.

Essential thrombocythemias without V617F JAK2 mutation are clonal hematopoietic stem cell disorders

Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM090

European LeukemiaNet study on the reproducibility of bone marrow features in masked polycythemia vera and differentiation from essential thrombocythemia.

Expression level and differential JAK2-V617F-binding of the adaptor protein Lnk regulates JAK2-mediated signals in myeloproliferative neoplasms.

Extramedullary blastic transformation revealed by a prolonged fever during the course of a 5q- syndrome

Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis

From leeches to interferon: should cytoreduction be prescribed for all patients with polycythemia vera?

Health-related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy

High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a

Identification of JAK2 mutations in canine primary polycythemia.

Impact of bone marrow fibrosis grade in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: A study of the MYSEC group

Impact of hydroxycarbamide and interferon-α on red cell adhesion and membrane protein expression in polycythemia vera.

Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts.

Interferon alfa in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms

Interferon alfa therapy in CALR-mutated essential thrombocythemia.

Interferon and the treatment of polycythemia vera, essential thrombocythemia and myelofibrosis

Interferon-alpha for the therapy of myeloproliferative neoplasms: targeting the malignant clone

Interferon-alpha in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms. Status and perspectives

Interferon-alpha therapy in bcr-abl-negative myeloproliferative neoplasms.

Interlaboratory development and validation of a HRM method applied to the detection of JAK2 exon 12 mutations in polycythemia vera patients

Is life expectancy of polycythemia vera patients clearly different from that of the general population?

Is there a role for the use of IFN-α in primary myelofibrosis?

Is there consensus on consensus?

JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis

Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study

Live and let (MPN cells) die!

Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis.

Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis.

Long-term follow-up of JAK2 exon 12 polycythemia vera: a French Intergroup of Myeloproliferative Neoplasms (FIM) study

Long-term incidence of hematological evolution in three French prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia.

Long-term outcomes of polycythemia vera patients treated with pipobroman as initial therapy

Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses.

Long-term treatment with interferon alfa for myeloproliferative neoplasms

Lu/BCAM-mediated cell adhesion as biological marker of JAK2V617F activity in erythrocytes of polycythemia vera patients.

Luspatercept for the treatment of anemia in myelodysplastic syndromes and primary myelofibrosis

Markers of iron deficiency in patients with polycythemia vera receiving ruxolitinib or best available therapy.

Megakaryocytes and platelets in myeloproliferative disorders

Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations

Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial

Mutations in exon 12 of JAK2 are mainly found in JAK2 V617F-negative polycythaemia vera patients.

Mutations with epigenetic effects in myeloproliferative neoplasms and recent progress in treatment: Proceedings from the 5th International Post-ASH Symposium